TechBio innovator spotlight: BIOS

BIOS health logo

BIOS Health is headquartered in Cambridge since 2015. Interview with Oliver Armitage, Chief Scientific Officer and Co-Founder

What does the company do?

BIOS is leveraging the nervous system to inform treatments and deliver therapies for chronic conditions. The company uses AI and machine learning technology to tap into the nervous system which acts as the controlling, regulatory and communication system for the body, connecting all organs to the brain and spinal cord.

“We can record and electrically stimulate the nervous system to understand both how a disease or an organ system is progressing, and how neural regulation is being done by the brain. We then use this information to intervene with drugs or devices that can help bring the organ back into a healthier state.” - Oliver Armitage, Chief Scientific Officer and Co-Founder

How does the technology work?

BIOS are specialists in collecting neural data and do it in a number of ways. Data can be taken directly from a patient either with an implant that transmits data from the nerve to the device, by minimally invasive collection through a bedside box, or proxies of neural data can be collected through wearable devices. Once the company has collected the data, it then uses two sets of AI and machine learning techniques. The first decodes the data coming from the nervous system and then a second set identifies recommendations for treatment and intervention based on the neural code. Oliver said: “By understanding the messaging from the nervous system and being able to decode that language and ‘speak nerve’, we can link up what's going on within whole subsets of patients and identify new treatment options.”

How will it be used?

BIOS’ solution is to build ‘neural digital therapies’. Neural digital therapy is a precision therapy developed using insights from neural recordings. These can range from precision bioelectronics and companion diagnostics to neural biomarker-assisted drug development. In 2020, BIOS launched the Autonomic Therapy Initiative (ATI) programme to realise a neural digital therapy for cardiovascular diseases that are responsible for a third of all deaths globally. The ATI programme leverages the BIOS approach of unique digital neural biomarkers and machine learning AI to offer a level of precision unseen before in healthcare. The programme will deliver personalised, real-time treatment recommendations, shaping the design of new therapies and even replace current drugs with computer-generated neural signals.

Oliver said: “Genomics data has been used by therapeutics companies to create medicines based on genome precision. What we have discovered is that the nervous system gives you the ability to target precision treatments on all of the chronic conditions that genetics aren’t as good at. Neural is the next wave of precision medicine”

The Future

BIOS is working to bring this whole new field of Neural Digital Therapies forward to enable neural-based precision medicine for chronic diseases where it would be deeply impactful. Oliver said: “We want to work with people with deep disease expertise, in more disease areas like inflammation, diabetes, respiratory, and neurological conditions, to bring forward the greater precision treatments that neural biomarkers and neural data allow us to do to those disease areas.”

More within